CRVS

+ Watchlist + Portfolio

Corvus Pharmaceuticals, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $15.40
52-Week Range: $5.03 – $26.95
Market Cap: $1.21B
P/E (TTM): —
EPS (TTM): -0.64
Dividend Yield: —

Advanced Metrics

Price/Book: 5.35
PEG Ratio: —
Return on Equity: -35.43%
Return on Assets: -21.66%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 16.16
Debt/Equity: 0.00
Total Debt: $728.00K
Free Cash Flow: $-27.40M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.08B

CRVS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$24.47M	$16.53M	$19.39M	$33.72M
Selling, General & Admin	$8.10M	$6.88M	$8.16M	$9.25M
Operating Expenses	$32.56M	$23.41M	$27.55M	$42.97M
Operating Income	-$32.56M	-$23.41M	-$27.55M	-$42.97M
EBITDA	-$32.20M	-$23.26M	-$27.46M	-$42.87M
Pretax Income	-$41.31M	-$27.03M	-$62.29M	-$15.28M
Net Income	-$41.31M	-$27.03M	-$62.29M	-$15.28M
Diluted EPS	-0.89	-0.56	-1.02	-0.53
Diluted Shares	46.55M	48.03M	60.99M	79.74M

CRVS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$13.16M	$12.62M	$8.74M	$4.58M
Receivables	$633.00K	$63.00K	$216.00K	$374.00K
Current Assets	$43.66M	$27.96M	$54.41M	$58.21M
Total Assets	$68.24M	$45.55M	$68.91M	$71.12M
Current Liabilities	$10.75M	$6.87M	$35.40M	$9.38M
Total Debt	$2.60M	$1.37M	$1.12M	$937.00K
Total Liabilities	$12.13M	$6.87M	$36.34M	$9.91M
Retained Earnings	-$307.69M	-$334.72M	-$397.01M	-$412.29M
Shareholders' Equity	$56.12M	$38.68M	$32.57M	$61.20M
Working Capital	$32.91M	$21.09M	$19.00M	$48.83M

CRVS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$27.02M	-$23.93M	-$25.42M	-$32.80M
Capital Expenditure	-$269.00K	-$34.00K	—	-$174.00K
Free Cash Flow	-$27.29M	-$23.97M	-$25.42M	-$32.97M
Depreciation & Amortisation	$367.00K	$151.00K	$85.00K	$105.00K
Stock-Based Compensation	$2.69M	$2.15M	$3.00M	$5.33M
Investing Cash Flow	-$23.28M	$15.54M	-$27.48M	-$7.80M
Financing Cash Flow	$0.00	$7.86M	$49.03M	$36.43M
Net Change in Cash	-$50.30M	-$539.00K	-$3.88M	-$4.16M

CRVS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$7.45M	$7.87M	$8.45M	$9.94M	$11.18M
Selling, General & Admin	$2.47M	$2.39M	$2.12M	$2.28M	$3.70M
Operating Expenses	$9.92M	$10.26M	$10.57M	$12.22M	$14.88M
Operating Income	-$9.92M	-$10.26M	-$10.57M	-$12.22M	-$14.88M
EBITDA	-$9.90M	-$10.23M	-$10.54M	-$12.19M	-$14.85M
Pretax Income	$15.19M	-$8.00M	-$10.16M	-$12.32M	-$13.69M
Net Income	$15.19M	-$8.00M	-$10.16M	-$12.32M	-$13.69M
Diluted EPS	-0.13	-0.10	-0.12	-0.15	-0.15
Diluted Shares	75.15M	77.77M	82.84M	82.96M	90.00M

CRVS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$5.00M	$14.69M	$2.87M	$4.58M	$40.10M
Receivables	$227.00K	$259.00K	$346.00K	$374.00K	$1.20M
Current Assets	$45.49M	$75.78M	$66.94M	$58.21M	$239.95M
Total Assets	$59.44M	$89.46M	$80.47M	$71.12M	$253.19M
Current Liabilities	$9.28M	$8.51M	$8.07M	$9.38M	$12.11M
Total Debt	$1.15M	$1.08M	$1.01M	$937.00K	$834.00K
Total Liabilities	$10.11M	$9.23M	$8.71M	$9.91M	$12.52M
Retained Earnings	-$381.82M	-$389.81M	-$399.97M	-$412.29M	-$425.99M
Shareholders' Equity	$49.33M	$80.23M	$71.77M	$61.20M	$240.68M
Working Capital	$36.21M	$67.28M	$58.87M	$48.83M	$227.84M

CRVS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$8.26M	-$5.78M	-$9.57M	-$9.19M	-$10.37M
Capital Expenditure	-$36.00K	-$113.00K	—	-$25.00K	-$91.00K
Free Cash Flow	-$8.30M	-$5.89M	-$9.57M	-$9.22M	-$10.46M
Depreciation & Amortisation	$22.00K	$29.00K	$28.00K	$26.00K	$29.00K
Stock-Based Compensation	$1.25M	$1.26M	$1.25M	$1.57M	$2.65M
Investing Cash Flow	$4.24M	-$20.30M	-$2.62M	$10.88M	-$144.85M
Financing Cash Flow	$279.00K	$35.77M	$360.00K	$20.00K	$190.75M
Net Change in Cash	-$3.74M	$9.69M	-$11.82M	$1.71M	$35.53M

Market Snapshot

About

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing precision oncology therapeutics. Headquartered in Burlingame, California, the company focuses on drugs that modulate the tumor microenvironment and immune system to treat cancer. Corvus' lead product candidate, mupadolimab, is an antibody targeting CD73 being evaluated in multiple tumor types including non-small cell lung cancer and head and neck cancer. The company's pipeline also includes ciforadenant, an adenosine A2A receptor antagonist, for various solid tumors.